Form 4: Milestone Pharmaceuticals Inc. Executive Awarded Stock Options and Restricted Stock Units

Chief Medical Officer David Bharucha receives stock options and restricted stock units from Milestone Pharmaceuticals Inc.

Summary

• On January 27, 2025, David Bharucha, Chief Medical Officer of Milestone Pharmaceuticals Inc., was granted employee stock options for 120,600 common shares and 80,400 restricted stock units.
• The stock options have an exercise price of $2.02 per share and expire on January 27, 2035.
• The options vest over time, with one-fourth vesting on January 27, 2026, and the remainder vesting monthly thereafter, contingent upon continued service.
• The restricted stock units each represent a right to receive one common share and vest in equal installments on January 27th of 2026, 2027, 2028 and 2029, also contingent upon continued service.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. It reflects standard executive compensation practices, incentivizing the Chief Medical Officer. There are no immediate negative implications.

Positives

• The grant of stock options and restricted stock units aligns the executive's interests with those of the shareholders.
• The vesting schedule incentivizes continued service and commitment from the Chief Medical Officer.

Risks

• The value of the stock options and restricted stock units is dependent on the future performance of Milestone Pharmaceuticals Inc.'s stock price.
• The executive must remain employed by the company to fully vest the awards.

Future Outlook

The document does not contain specific forward-looking statements, but the equity grants suggest an expectation of future value creation at Milestone Pharmaceuticals.

Industry Context

Equity compensation is a common practice in the pharmaceutical industry to attract, retain, and incentivize key executives.

Comparison to Industry Standards

• Stock option and RSU grants are standard practice for executive compensation in the pharmaceutical industry.
• Vesting schedules are typically tied to continued employment to ensure alignment with company goals, similar to practices at companies like Amgen, Pfizer, and Johnson & Johnson.
• The specific number of shares and vesting terms would need to be compared to peer companies of similar size and stage of development to determine if they are in line with industry norms.

Stakeholder Impact

• Shareholders may view the equity grants as a positive sign, aligning management's interests with the company's long-term success.
• Employees may see the grants as a sign of confidence in the company's future.

Key Dates